Skip to main content

Harry Paul Erba CV

Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
DUMC Box 3961, Durham, NC 27710
2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
CV

Overview


I am a clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine.  I serve as Director of the Leukemia Program and Director of Phase I Development in Hematologic Malignancies.  I am also the Chair of the SWOG Leukemia Committee.  I am interested in the clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis), and acute lymphoblastic leukemia.  Specifically, I have been the Principal Investigator for small molecular inhibitors, antibody-drug conjugates and cytotoxic chemotherapy.

Office Hours


Office hours:
Monday, 8 a.m. to 12 p.m.
Tuesday, 8 a.m. to 5 p.m.
Wednesday, 8 a.m. to 12 p.m.
Friday, 1 p.m. to 5 p.m.

Current Appointments & Affiliations


Professor of Medicine · 2023 - Present Medicine, Hematologic Malignancies and Cellular Therapy, Medicine
Member of the Duke Cancer Institute · 2018 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


Frontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted Agents.

Journal Article Am J Hematol · March 2025 Backbone therapy for acute myeloid leukemia for younger adults has for 50 years been based on a combination of cytarabine and anthracycline. Over the past 10 years the addition of several targeted agents has been found to improve the outcomes of subsets of ... Full text Link to item Cite
View All Publications

Recent Grants


CL04-ORY-1001

Clinical TrialPrincipal Investigator · Awarded by Oryzon Genomics SA · 2023 - 2028

Novartis Phase II MBG453 in combination with Venetoclax and Azacitidine in AML

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2020 - 2028

View All Grants

Education, Training & Certifications


Medical Licensure Commission of Alabama · 2012 Lic.
Stanford University, School of Medicine · 1988 M.D.
Stanford University · 1988 Ph.D.